Introduction {#Sec1}
============

Oral bisphosphonates (especially alendronate and risedronate) remain the standard of care for the treatment of osteoporosis. Poor adherence to oral bisphosphonates due to instructions for use and gastrointestinal side effects represents however a concern \[[@CR1]\]. Approximately 75% of women who initiate oral bisphosphonates were shown to be non-adherent within 1 year and 50% discontinued therapy by this time \[[@CR2]\], leading to a substantial decrease of the potential benefits of the drugs \[[@CR3]\]. All oral bisphosphonates require patients to follow strict dosing instructions to derive the full benefits, i.e., the intake of the drug on an empty stomach at least 30 to 60 min before the first food, drink, or other medication of the day \[[@CR4]\].

Recently, weekly gastro-resistant (GR) risedronate tablets (also called delayed-release formulation of risedronate) were developed to facilitate its use and decrease potential side effects with elimination of the need for fasting without affecting its bioavailability and efficacy. This formulation provides thus a more convenient dosing regimen for oral bisphosphonate therapy, allowing patients to take their weekly risedronate immediately after breakfast. Clinical studies have confirmed that 35 mg GR risedronate is similar in efficacy and safety than risedronate 5 mg daily \[[@CR4], [@CR5]\].

GR risedronate tablets are thus expected to be associated with improved persistence compared to common oral bisphosphonates, but they are also slightly more expensive. Considering the limited healthcare resources available, it has become important for decision makers to allocate healthcare resources efficiently \[[@CR6]\], and the question whether risedronate GR is cost-effective or not compared with the most relevant alternative treatments (i.e., weekly alendronate and generic risedronate) is thus highly relevant. Economic evaluations that compare interventions in terms of costs and outcomes are nowadays increasingly important and used by decision makers, especially for pricing and reimbursement decisions.

The aim of this study was therefore to assess the cost-effectiveness of GR risedronate compared to weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France.

Methods {#Sec2}
=======

A previously validated Markov microsimulation model \[[@CR7]\] was used to estimate the cost-effectiveness of GR risedronate compared to weekly alendronate, generic risedronate, and no treatment from the French payer perspective. The model was built up using TreeAge Pro 2017 (TreeAge Pro Inc., Williamston, MA, USA) and adheres to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement \[[@CR8]\]. A description of the model is provided here below; most data are included in Table [1](#Tab1){ref-type="table"} and additional information could be found in previous studies \[[@CR7], [@CR17]\], including an analysis that assessed the public health impact and economic evaluation of vitamin D--fortified dairy products for fracture prevention in France \[[@CR18]\].Table 1Incidence of fractures, costs, utilities, and treatment effects used in the modelParameterIncidence of fracture (rate/100) \[[@CR9], [@CR10]\] Hip0.055 (60--64 years), 0.098 (65--69 years), 0.199 (70--74 years), 0.462 (75--79 years), 0.915 (80--84 years), 2.312 (85+) Vertebral0.097 (60--64 years), 0.142 (65--69 years), 0.280 (70--74 years), 0.450 (75--79 years), 0.575 (80--84 years), 1.087 (85+) Wrist0.207 (60--64 years), 0.238 (65--69 years), 0.356 (70--74 years), 0.451 (75--79 years), 0.573 (80--84 years), 0.986 (85+) Other0.211 (60--64 years), 0.335 (65--69 years), 0.563 (70--74 years), 0.973 (75--79 years), 1.557 (80--84 years), 3.884 (85+)Direct fracture cost (€2017) \[[@CR9], [@CR11], [@CR12]\] Hip, first 6 months12,081 Hip, yearly long-term3387 (\< 70 years)--6807 (≥ 70 years) CV, first 6 months5929 Wrist, first 6 months2144 Other, first 6 months5778Health state utility values \[[@CR13], [@CR14]\] General population0.766 Hip (1st year/ subs. years)0.55 (0.53--0.57)/0.86 (0.84--0.89) CV (1st year/ subs. years)0.68 (0.65--0.70)/0.85 (0.82--0.87) Wrist (1st year/ subs. years)0.83 (0.82--0.84)/0.99 (0.97--1.00) Other (1st year/ subs. years)0.91 (0.88--0.94)/0.99 (0.97--1.00)Treatment effects of oral bisphosphonates (relative risk of fracture) \[[@CR15]\] Hip0.74 (0.59--0.93) CV0.61 (0.50--0.75) Wrist0.68 (0.43--1.08) Other0.76 (0.64--0.91)Drug cost (for 12 weeks) \[[@CR16]\] GR risedronate49.04 Generic risedronate31.67 Alendronate46.28GP visit23BMD measurement39.96*CV*, clinical vertebral; *subs*., subsequent; *y*, years

Model structure {#Sec3}
---------------

A Markov microsimulation model was used to allow tracking patient characteristics and individual disease histories (e.g., fractures and residential status) and avoid unnecessary transition restrictions. The model health states were no fracture, death, hip fracture, clinical vertebral fracture, wrist fracture, and other fracture. The "other fracture" state includes other osteoporotic fractures as defined by the IOF-EFPIA report \[[@CR9]\]. We used a lifetime horizon and a 6-month cycle. Patients could experience multiple fractures at the same site or multiple sites. Discount rates of 3% for both costs and health benefits were used.

Populations {#Sec4}
-----------

Analyses were conducted for postmenopausal women aged 60 to 80 years with bone mineral density (BMD) T-score ≤ − 2.5 and/or prevalent vertebral fractures, in line with current reimbursement conditions for oral bisphosphonates in France.

Fracture risk {#Sec5}
-------------

Incidence of hip fractures in the general French population was derived from the study of Briot et al. \[[@CR10]\] using data from the year 2013. Since this study only reported incidence data for large age groups (e.g., 60--74 years), an adjustment was made based on the IOF-EFPIA report \[[@CR9]\] to estimate a 5-year incidence rate and thus take into account that fracture risk is increasing over time. As no data for the incidence of other osteoporotic fractures (i.e., clinical vertebral, wrist, and other fractures) are available in France, we applied the age-specific ratio incidence from other countries in line with the methodology used by the IOF-EFPIA report \[[@CR9]\].

Initial fracture probabilities were then adjusted to accurately reflect the fracture risk in the target population in comparison with that of the general population using previously validated methods \[[@CR19], [@CR20]\]. Fracture risk was also adjusted when a new fracture occurred during the simulation process, as previously done \[[@CR17]\].

Baseline mortality data for the general population was derived from the French National Institute of Statistics and Economic Studies (INSEE) for the years 2013--2015 \[[@CR21]\]. We further assumed an increased mortality after hip fracture and clinical vertebral fracture in line with previous studies \[[@CR17]\]. Because excess mortality may also be attributable to comorbidities, we further took into account that only 25% of the excess mortality following fractures was attributable to the fractures themselves \[[@CR22], [@CR23]\].

Fracture cost {#Sec6}
-------------

We used a healthcare perspective for the cost estimation. The costs of hip and wrist fractures were derived from the study of Bouee et al. \[[@CR11]\]. The cost of clinical vertebral fracture was derived from a previous cost-effectiveness analysis in France \[[@CR12]\], and the cost of other fractures was quantified relative to hip fracture in line with the assumption used in the IOF-EFPIA report \[[@CR9]\]. All costs were expressed in €2017 and adjusted using the national price index (health index).

Hip fractures are also associated with long-term costs. These long-term costs were based on the proportion of patients being admitted in nursing home following the fracture. Based on the study of Drame et al. \[[@CR24]\], 20.1% of patients were institutionalized after a hip fracture in French population aged above 75 years. For patients aged between 60 and 74 years, we conservatively assumed that only 10% were institutionalized in line with international studies \[[@CR9]\]. The annual cost of living in nursing home that was reduced by 10% to take into account that patients could have been institutionalized later in their life was estimated at €37,629 \[[@CR25]\]. Non-hip fractures were not associated with long-term costs.

We also incorporated a higher cost for a recurrent fracture at the same type within the model, in line with a recent study suggesting that patients who experienced a subsequent fracture had significantly higher healthcare costs than patients with a first fracture \[[@CR26]\]. The proportion factor (1.68) derived from the study of Weaver et al. \[[@CR26]\] was thus applied.

Utility values {#Sec7}
--------------

Baseline utility value in the general French population was estimated at 0.766 \[[@CR13]\]. The effects of fractures on utility were derived from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) study \[[@CR14]\]. This study is the largest study assessing the quality of life of patients with fractures from 11 countries including 2808 patients. Since other fractures were not included in the ICUROS study, we used estimate from a previous systematic review \[[@CR27]\]. An additional effect on utility after multiple fractures was modeled as previously done \[[@CR17]\].

Treatment effects {#Sec8}
-----------------

In the absence of studies suggesting a clear and significant difference in treatment effects between oral bisphosphonates (alendronate and risedronate) \[[@CR28]\], the National Institute for Clinical Health and Excellence (NICE) in the UK has suggested that pooling the efficacy results for bisphosphonates is appropriate \[[@CR29]\]. We therefore used results of a meta-analysis of pooled data from the alendronate and risedronate studies conducted by ScHARR \[[@CR15]\]. This study suggests that oral bisphosphonates resulted in a relative risk (RR) of 0.58 for vertebral fracture (95% CI, 0.51 to 0.67; seven RCTs; *n* = 9340), a RR of 0.71 for hip fracture (95% CI, 0.58 to 0.87; six RCTs; *n* = 19,233), an RR of 0.69 for wrist fracture (95% CI, 0.45 to 1.05; six RCTs; *n* = 1037), and a RR for other non-vertebral fractures of 0.78 (95% CI, 0.69 to 0.88; 11 RCTs; *n* = 22,372) that was used for other fractures in the model. These RRs were used for all oral bisphosphonates, including generics. After stopping medication, it was assumed a linear decrease of the effects for a duration similar to the duration of therapy, in line with previous economic analyses of oral bisphosphonates \[[@CR30]\] and clinical data \[[@CR31]\].

Medication persistence defined as a dichotomized variable (persistent or not) as to whether a patient continued therapy beyond an elapsed time period was included in the model, as previously done \[[@CR32], [@CR33]\]. Patients were at risk of discontinuation every 6 months within 3 years. For patients who stopped taking their therapy, the treatment cost immediately stopped and the offset-time period started at the same time. For those who discontinued therapy within 6 months, no treatment effect was received \[[@CR32], [@CR33]\], since at least 6 months of treatment is necessary to reduce the risk of fractures \[[@CR34]\].

Persistence data up to 3 years was extracted from the NostraData pharmacy panel of over 3500 stores, representing 65--70% of all dispensed scripts in Australia. The oral bisphosphonate usage of patients who initiated to the market between January 2012 and December 2015 was extracted for this analysis, and a permissible gap of 180 days was selected. In total, data from 165,017 patients were analyzed. Patients who switched from their therapy to a non-bisphosphonate therapy (e.g., denosumab) were identified and excluded from the persistency analysis, leaving a total of 151,422 patients within the final analysis. This cohort of patients was then tracked from January 2012 through April 2017. Persistence data for risedronate were conservatively also used for generic risedronate, even if persistence has been shown to be lower for generic drugs \[[@CR35]\]. The probability of persistence with GR risedronate, risedronate, and weekly alendronate over time is shown in Fig. [1](#Fig1){ref-type="fig"}. At 1 year, more patients were persistent with GR risedronate (39%) compared to weekly alendronate (33%) and weekly risedronate (24%). At the end of the 3-year period, respectively, 12%, 9%, and 5% were persistent with GR risedronate, weekly alendronate, and weekly risedronate.Fig. 1Persistence rates to oral bisphosphonates up to 3 years

Treatment cost includes drug costs and monitoring. The drug prices were derived from *Ameli* on 26 February 2018 \[[@CR16]\] (see Table [1](#Tab1){ref-type="table"}). We also assigned the cost of one general physician visit every 6 months of treatment (for persistent patients) and the cost of one bone density measurement at year 1. Adverse events observed with oral bisphosphates are generally mild and transient. The cost and quality of life impact of adverse events would thus only be minor and not affect the results and were therefore not included in the analysis.

Analyses {#Sec9}
--------

A total of 1,000,000 of trials were run for each analysis. Total costs, disaggregated costs (i.e., treatment costs that include drug costs adjusted by persistence and monitoring costs, and fracture-related costs), and accumulated QALYs were estimated for each treatment. If GR risedronate is associated with more QALYs and less costs than an alternative, it is considered dominant or cost-saving (when compared to no treatment). If GR risedronate provides more QALYs and more costs, then we computed the incremental cost-effectiveness ratio (ICER) defined as the difference between GR risedronate and the comparator treatment in terms of total costs (expressed in €2017) divided by the difference between them in terms of QALYs. The ICER represents then the additional cost per QALY gained of GR risedronate. If the ICER is above a certain threshold, then the cost is too high for the benefits and the intervention is not considered as cost-effective. In France, no specific threshold is actually used for defining cost-effectiveness. The World Health Organization has suggested a value of three times the gross domestic product (GDP) per capita as the QALY value to be used as cost-effectiveness threshold in developed countries. Borgström et al. \[[@CR36]\] have suggested a threshold for QALY equal to two times the GDP per capita for industrialized countries (+ − €86,000 in France). This assumption has been used for defining fracture risk thresholds in several countries \[[@CR37], [@CR38]\].

Sensitivity analyses were then systematically performed to assess the impact of model parameters on the results. One-way sensitivity analyses assessed the impact of single parameters on the results and were conducted on discount rates, fracture costs, fracture risks, fracture disutility, mortality, and treatment costs. Sensitivity analyses were also conducted on medication persistence varying by ± 25% and ± 50% the incremental difference in persistence between GR risedronate and each active comparator. We also conducted one sensitivity analysis where treatment-specific efficacy data (alendronate and risedronate) were used, derived from the NICE appraisal \[[@CR15]\]. Probabilistic sensitivity analyses were also undertaken to examine the effect of the joint uncertainty surrounding the model variables. Nearly all parameters were varying simultaneously over plausible range of values. To perform this probabilistic analysis, a specific distribution was attributed to each parameter around the point estimate used in the base-case analysis, including for medication persistence. We followed guideline \[[@CR39]\] for the selection of distributions and used 95% confidence intervals when available. A report including all distributions and values is available at the corresponding author per request.

Results {#Sec10}
=======

Base-case analysis {#Sec11}
------------------

Table [2](#Tab2){ref-type="table"} presents the total and disaggregated healthcare costs, accumulated QALYs, the incremental costs and QALY, and the ICER (expressed in cost per QALY gained) of GR risedronate compared with generic risedronate, alendronate, and no treatment. In women aged 70 years with BMD T-score ≤ − 2.5 and prevalent vertebral fractures, GR risedronate is associated with a €153 higher treatment cost compared to generic risedronate, but leads to a €132 reduction in fracture costs resulting from the improved persistence. The incremental total healthcare cost of GR risedronate was thus estimated at + €21 (€153--€132), while GR risedronate is associated with 0.090 additional QALY gained. The cost per QALY gained of GR risedronate was thus estimated at €2341 (= €21/0.090) per QALY gained compared to generic risedronate and at €2037 compared to alendronate.Table 2Lifetime healthcare costs, QALYs, and incremental cost-effectiveness ratio (cost (€) per QALY gained) of GR risedronate compared with generic risedronate, alendronate, and no treatment at the age of 70 yearsGR risedronateGeneric risedronateAlendronateNo treatmentIncrementalVs generic risedronateVs alendronateVs no treatmentBMD T-score ≤ − 2.5 and prevalent vertebral fractures Treatment cost343191298015345343 Fractures-related cost27,05127,18227,09127,418− 132− 40− 367 Total healthcare cost27,39427,37327,39027,418215− 24 QALY9.49029.48129.48819.46640.00900.00210.0238 ICER (€ per QALY gained)23412037Cost-saving\*BMD T-score ≤ − 2.5 Treatment cost343191298015245343 Fractures-related cost16,70616,74316,72816,898− 37− 22− 192 Total healthcare cost17,05016,93317,02616,89811724152 QALY10.067410.062110.065510.05640.00530.00190.011 ICER (€ per QALY gained)21,87512,54813,707Prevalent vertebral fractures Treatment cost343191298015245343 Fractures-related cost15,87815,92915,89916,029− 51− 21− 151 Total healthcare cost16,22116,11916,19816,02910223192 QALY9.88819.88309.88689.87360.00510.00130.0145 ICER (€ per QALY gained)19,92218,25913,311*GR*, gastro-resistant; *ICER*, incremental cost-effectiveness ratio; *QALY*, quality-adjusted life year\*Additional treatment costs lower than fractures-related cost saved with more prevented fractures

Compared to no treatment, the treatment costs of GR risedronate (€343) was lower than the saved costs (€367) resulting from the prevention of additional fractures induced by the improved persistence. GR risedronate is thus cost-saving compared to no treatment. From the age of 75 years, GR risedronate is dominant (more QALY for less total costs) compared to both generic risedronate and alendronate.

Additional scenarios {#Sec12}
--------------------

In women aged 70 years with BMD T-score ≤ − 2.5 or prevalent vertebral fractures only, the cost per QALY gained of GR risedronate falls below €25,000 for all comparators (Table [2](#Tab2){ref-type="table"}). Additional scenarios on the age range 60--80 years were conducted (Table [3](#Tab3){ref-type="table"}). GR risedronate was dominant/cost-saving compared to all comparators in all women aged 80 years and over. In all of the simulated populations, GR risedronate was cost-effective compared to generic risedronate, alendronate, and no treatment at a threshold of €60,000 per QALY gained.Table 3Incremental cost-effectiveness ratio (cost (€) per QALY gained) of GR risedronate compared with generic risedronate, alendronate, and no treatment for women aged 60--80 yearsGR risedronateVs generic risedronateVs alendronateVs no treatmentBMD T-score ≤ − 2.5 and prevalent vertebral fractures 60 years18,29516,46812,545 65 years806711,9853443 70 years23412037Cost-saving\* 75 yearsDominant\*\*DominantCost-saving 80 yearsDominantDominantCost-savingBMD T-score ≤ − 2.5 60 years55,40932,79040,117 65 years33,66427,45722,295 70 years21,87512,54813,707 75 yearsDominant9811Cost-saving 80 yearsDominantDominantCost-savingPrevalent vertebral fractures 60 years46,64143,91334,963 65 years33,66427,45722,295 70 years19,92218,25913,311 75 years16829585Cost-saving 80 yearsDominantDominantCost-saving\*Additional treatment costs lower than fractures-related cost saved with more prevented fractures\*\*Lower costs for more QALYs

Sensitivity analyses {#Sec13}
--------------------

Table [4](#Tab4){ref-type="table"} reports the results of the one-way sensitivity analyses in women aged 70 years with BMD T-score ≤ − 2.5 and prevalent vertebral fractures. The ICERs of GR risedronate were shown to be markedly affected by the incremental difference in persistence between GR risedronate and the active comparator treatment. Other analyses further suggested that the ICERs of GR risedronate were shown to moderately increase when decreasing fracture costs or fracture disutilities, when using discount rates of 5% and when treatment cost is increasing. In all these sensitivity analyses, the ICERs of GR risedronate remain below €10,000 for all comparators, except when using treatment-specific efficacy data where GR risedronate was dominated (more costs, less QALYs) by weekly alendronate.Table 4One-way sensitivity analyses on the incremental cost-effectiveness ratio of GR risedronate compared to generic risedronate, alendronate, and no treatment in women aged 70 years with BMD T-score ≤ − 2.5 and prevalent vertebral fracturesGR risedronateVs generic risedronateVs alendronateVs no treatmentBase-case23412037Cost-savingFracture costs 25% lower556480384484Fracture costs 25% higherDominantDominantCost-savingFracture disutilities 25% higher3913624Cost-savingFracture disutilities 25% lower24818860912Discount rates 5%74537921937Excess mortality (50%)29531279446GR risedronate cost + 10%616417,978425GR risedronate cost − 10%DominantDominantCost-savingTreatment-specific efficacy data5141Dominated2071Incremental persistence + 50%4811272--Incremental persistence + 25%7381398--Incremental persistence − 25%62704349--Incremental persistence − 50%13,8029494--

The results of the probabilistic sensitivity analyses are provided in Fig. [2](#Fig2){ref-type="fig"} where the cost-effectiveness acceptability curves show the probability that GR risedronate is cost-effective compared to the other comparator for different willingness to pay of decision makers per QALY gained. The curves suggest that GR risedronate was cost-effective in at least 50% of the simulations for thresholds up to €100,000 per QALY gained. At a threshold of €85,000 per QALY gained (= 2 × GDP in France), in women aged 70 years, GR risedronate was cost-effective in 98%, 79%, and 58% compared to no treatment, generic risedronate, and alendronate, respectively.Fig. 2Cost-effectiveness acceptability curves of GR risedronate versus generic risedronate (**a**), alendronate (**b**), and no treatment (**c**) in women aged 60, 70, and 80 years with prevalent vertebral fractures and a BMD T-score ≤ − 2.5

Discussion {#Sec14}
==========

This study suggests that GR risedronate is cost-effective compared with weekly alendronate, generic risedronate, and no treatment in France. In all of the simulated populations, the ICERs of GR risedronate were below €60,000 per QALY gained and GR risedronate could thus be considered as a cost-effective option. The cost-effectiveness of GR risedronate improved with increasing patient age and fracture risk at baseline, as the benefits of improved persistence become higher when increasing the fracture risk of the population. So, in women with a BMD T-score ≤ − 2.5 and prevalent vertebral fractures, the cost per QALY gained of GR risedronate compared to alendronate, generic risedronate, and no treatment was always below €20,000 per QALY gained. In women aged 75 years and older, GR risedronate was even shown to be dominant (more QALYs, less costs) compared to generic risedronate and alendronate, and cost-saving (more QALYs, lower total costs than no treatment) in women aged 70 years and over. Sensitivity analyses suggest that results are most sensitive to the incremental difference in persistence between GR risedronate and the active comparators.

To our knowledge, this study provides the first results about the cost-effectiveness of GR risedronate for the treatment of postmenopausal women with osteoporosis. Previous studies have already shown that risedronate is cost-effective compared to no treatment \[[@CR28], [@CR40]\]. Our study further confirms the importance of medication persistence in pharmacoeconomic analysis in osteoporosis \[[@CR41]\], suggesting that a more expensive drug with improved persistence has the potential to be cost-effective. One strength of our study is the use of a large longitudinal database to assess persistence to all medications. Persistence data were however derived from an Australian study since GR risedronate was not yet used in France. In another Canadian study including a sample of 48,631 patients that initiated an oral bisphosphonate for the first time from July 2012 to November 2013 \[[@CR42]\], higher adherence defined as the percentage of patients retained after 12 months following initiation was also observed for GR risedronate compared to weekly alendronate and risedronate. We could thus expect similar higher persistence with GR risedronate in France, although it would be important in the future to collect persistence data to GR risedronate in France to confirm our results.

There are some additional potential limitations to this study. First, although the results were robust over all scenarios and sensitivity analyses, GR risedronate was dominated by weekly alendronate when including treatment-specific efficacy data for alendronate and risedronate. There is however no evidence of a difference in effect on fractures between bisphosphonates \[[@CR28]\], and the NICE has suggested that pooling the efficacy results for bisphosphonates is appropriate \[[@CR29]\] in line with our base-case assumption. Second, our analyses were conducted in women with BMD T-score ≤ − 2.5 and/or prevalent vertebral fractures in line with current reimbursement criteria for osteoporotic treatment in France. Further assessment of the cost-effectiveness of GR risedronate in other populations (e.g., based on FRAX score or in patients with an imminent risk fracture) could be interesting. Third, only persistence data were available and used in this analysis. We did not model the fact that patients could not take adequately all prescribed drugs (defined as medication adherence). Fourth, this analysis was limited to the most relevant comparators from the same therapeutic class (i.e., the traditional oral bisphosphonates: weekly alendronate and generic risedronate) for which persistence data were available in the persistence database. Other treatments such as denosumab or yearly intravenous are also available to treat osteoporosis. It would be interesting in the future to investigate the cost-effectiveness of GR risedronate compared to other drugs although this comparison could be more uncertain given the absence of direct comparison of efficacy between drugs.

Other potential limitations are related to the model and data. The most important are availability of data. Although data used to construct the model were based on French literature whenever possible, some data were derived from other countries. In particular, the effects of fracture on utility were not derived from a French study. However, we used an international multinational study (ICUROS), the largest study worldwide assessing the effects of fractures on quality of life. Previous economic analyses have already been conducted in France using this model \[[@CR18], [@CR43]\].

In conclusion, this study provides the first economic results about GR risedronate, suggesting that GR risedronate is a cost-effective strategy compared with alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France. As our results were most sensitive to the incremental difference in persistence between active drugs, it would be important to confirm the improved persistence associated with GR risedronate in other studies. GR risedronate may therefore represent a convenient and cost-effective dosing regimen for oral bisphosphonate therapy to treat osteoporosis.
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